Table 2

Lp(a) levels in relation to CVEs in patients with different glucose metabolism

Lp(a) (mg/dL)Events/subjects (435/5,143)HR (95% CI)
Crude modelAdjusted model
NGR
 Lp(a) per-SD increase1.226 (0.966–1.556)1.190 (0.880–1.609)
 Lp(a) <1015/361RefRef
 10 ≤ Lp(a) < 3021/3261.560 (0.804–3.026)1.830 (0.899–3.727)
 30 ≤ Lp(a) < 506/1181.053 (0.383–2.896)1.508 (0.530–4.292)
 Lp(a) ≥5014/1622.110 (1.018–4.371)*2.369 (1.091–5.144)*
Pre-DM
 Lp(a) per-SD increase1.344 (1.187–1.521)*1.327 (1.142–1.541)*
 Lp(a) <1049/7741.538 (0.863–2.743)1.600 (0.844–3.033)
 10 ≤ Lp(a) < 3054/7471.747 (0.986–3.095)1.639 (0.865–3.108)
 30 ≤ Lp(a) < 5027/3252.019 (1.074–3.794)*2.181 (1.099–4.327)*
 Lp(a) ≥5042/3922.710 (1.506–4.878)*2.668 (1.383–5.415)*
DM
 Lp(a) per-SD increase1.340 (1.199–1.498)*1.386 (1.217–1.578)*
 Lp(a) <1050/7281.665 (0.935–2.964)1.622 (0.858–3.068)
 10 ≤ Lp(a) < 3077/6602.844 (1.636–4.946)*2.594 (1.396–4.820)*
 30 ≤ Lp(a) < 5031/2582.978 (1.608–5.517)*3.088 (1.535–5.895)*
 Lp(a) ≥5049/2924.196 (2.353–7.482)*3.470 (1.801–6.686)*
  • Model adjusted for age, sex, BMI, smoking, hypertension, family history of CAD, GS, LVEF, creatinine, LDL cholesterol, HDL cholesterol, TG, NT-proBNP, big ET-1, fibrinogen, and baseline statins.

  • *For P < 0.05.